HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Magnus Ingelman-Sundberg Selected Research

Cytochrome P-450 CYP1A1 (CYP1A1)

8/2013Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.
5/2008CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations.
12/2005Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study.
5/2003CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls.
5/2003Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Magnus Ingelman-Sundberg Research Topics

Disease

23Neoplasms (Cancer)
11/2022 - 03/2002
18Hepatocellular Carcinoma (Hepatoma)
01/2020 - 03/2003
15Drug-Related Side Effects and Adverse Reactions
01/2022 - 01/2004
9Carcinogenesis
07/2021 - 02/2003
8Lung Neoplasms (Lung Cancer)
05/2008 - 05/2002
7Colonic Neoplasms (Colon Cancer)
02/2016 - 10/2007
6Fibrosis (Cirrhosis)
03/2024 - 01/2020
6Colorectal Neoplasms (Colorectal Cancer)
01/2016 - 03/2009
6Genetic Predisposition to Disease (Genetic Predisposition)
01/2015 - 08/2002
5Inflammation (Inflammations)
01/2023 - 04/2004
5Liver Diseases (Liver Disease)
10/2022 - 08/2013
5Breast Neoplasms (Breast Cancer)
01/2021 - 04/2003
4Alcoholic Liver Diseases (Alcoholic Liver Disease)
07/2021 - 04/2004
4Necrosis
03/2008 - 04/2004
3Non-alcoholic Fatty Liver Disease
03/2024 - 12/2019
3Liver Neoplasms (Liver Cancer)
07/2021 - 10/2002
3Fatty Liver
07/2020 - 03/2008
2Cardiovascular Diseases (Cardiovascular Disease)
02/2024 - 02/2011
2Liver Cirrhosis (Hepatic Cirrhosis)
01/2024 - 01/2020
2Alcoholic Fatty Liver
01/2022 - 01/2020
2Psychotic Disorders (Schizoaffective Disorder)
01/2021 - 01/2020
2Adrenocortical Carcinoma
01/2016 - 01/2016
2Neoplasm Metastasis (Metastasis)
01/2016 - 07/2014
2Infections
08/2013 - 02/2011
1Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy)
02/2024
1Genetic Risk Score
02/2024
1Atrophy
01/2023
1Ataxia (Dyssynergia)
01/2023
1Movement Disorders (Movement Disorder)
01/2023
1Hepatic Insufficiency
01/2023
1Treatment-Resistant Schizophrenia
01/2023
1Metaplasia
10/2022
1Dysbiosis
07/2020

Drug/Important Bio-Agent (IBA)

28EnzymesIBA
01/2022 - 03/2002
19Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
01/2021 - 09/2003
9Proteins (Proteins, Gene)FDA Link
10/2022 - 07/2002
8Cytochrome P-450 CYP2E1 (CYP2E1)IBA
07/2021 - 07/2002
7Ethanol (Ethyl Alcohol)IBA
07/2020 - 02/2003
6Biomarkers (Surrogate Marker)IBA
10/2022 - 06/2004
6Cytochrome P-450 CYP3AIBA
01/2020 - 12/2005
5CytokinesIBA
01/2023 - 03/2003
5Messenger RNA (mRNA)IBA
07/2020 - 09/2005
5ProdrugsIBA
01/2016 - 12/2010
5DuocarmycinsIBA
01/2015 - 06/2013
5Cytochrome P-450 CYP1A1 (CYP1A1)IBA
08/2013 - 05/2003
5CytochromesIBA
03/2011 - 12/2002
5CarcinogensIBA
01/2010 - 08/2002
4Cytochrome P-450 CYP2C19IBA
02/2024 - 05/2010
4AntibodiesIBA
01/2016 - 04/2004
4Transcription Factors (Transcription Factor)IBA
06/2010 - 04/2004
4Environmental CarcinogensIBA
12/2005 - 08/2002
4Estrogens (Estrogen)FDA Link
01/2005 - 04/2003
3Nonesterified Fatty Acids (NEFA)IBA
03/2024 - 01/2023
3LuciferasesIBA
11/2010 - 02/2004
3Hormones (Hormone)IBA
01/2005 - 09/2003
2Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
02/2024 - 10/2015
2Antipsychotic Agents (Antipsychotics)IBA
01/2021 - 01/2020
2NitritesIBA
01/2019 - 07/2002
2(5- chloro- 1H- indol- 2- yl)(1- (chloromethyl)- 1,2- dihydropyrrolo(3,2- e)indol- 3(6H)- yl)methanoneIBA
10/2013 - 06/2013
2Cytochrome P-450 CYP1A2 (CYP1A2)IBA
06/2009 - 09/2003
2Reactive Oxygen Species (Oxygen Radicals)IBA
03/2009 - 06/2004
2AutoantibodiesIBA
11/2008 - 02/2003
2ChemokinesIBA
09/2008 - 03/2008
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
03/2008 - 09/2005
2NicotineFDA Link
02/2006 - 10/2002
2Polychlorinated Dibenzodioxins (TCDD)IBA
01/2005 - 09/2003
2Free RadicalsIBA
06/2004 - 02/2003
1Conditioned Culture MediaIBA
03/2024
1Tissue Inhibitor of MetalloproteinasesIBA
03/2024
1Matrix Metalloproteinases (MMPs)IBA
03/2024
1AnticoagulantsIBA
02/2024
1MYK-461IBA
02/2024
1Small Interfering RNA (siRNA)IBA
01/2024
1KetanserinIBA
01/2024
15-HT2A Serotonin Receptor (5 HT2A Receptor)IBA
01/2024
1sarpogrelateIBA
01/2024
1Serotonin ReceptorsIBA
01/2024
1VimentinIBA
01/2024
1pimavanserinIBA
01/2024
1Serotonin (5 Hydroxytryptamine)IBA
01/2024
1Interleukin-6 (Interleukin 6)IBA
01/2023
1Clozapine (Clozaril)FDA LinkGeneric
01/2023
1Complement System Proteins (Complement)IBA
11/2022
1Oxygen (Dioxygen)IBA
07/2021
1Anesthetics (Anesthetic Agents)IBA
07/2021
1Acetaminophen (Paracetamol)FDA LinkGeneric
07/2021
1TamoxifenFDA LinkGeneric
01/2021
1Cytochrome P-450 CYP2D6 (CYP2D6)IBA
01/2021
1Caseins (Casein)FDA Link
07/2020
1Soybean Proteins (Soy Protein)IBA
07/2020
1cocoa butterIBA
07/2020
1Olive OilIBA
07/2020
1Diethylnitrosamine (N-Nitrosodiethylamine)IBA
07/2020
1Dietary ProteinsIBA
07/2020
1Dietary Fats (Dietary Fat)IBA
07/2020

Therapy/Procedure

11Therapeutics
01/2022 - 03/2006
5Drug Therapy (Chemotherapy)
02/2024 - 09/2005
2Enteral Nutrition (Feeding, Tube)
03/2008 - 09/2005
1Liver Transplantation
03/2024
1Duration of Therapy
01/2023